Dynavax (DVAX) Misses Q1 EPS by 2c

Dynavax (NASDAQ: DVAX) reported Q1 EPS of $0.22, $0.02 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $114 million versus the consensus estimate of $154.3 million.

GUIDANCE:

Dynavax anticipates 2022 revenues, operating expenses, and other costs to be in the ranges shown below, unchanged from the Company\'s previous financial guidance provided on February 28, 2022:

Full-year CpG 1018 adjuvant net product revenues of at least $550 million, with an associated gross margin of approximately 50%
Research and development expenses to be between approximately $55 - $70 million
Selling, general and administrative expenses to be between approximately $120 - $140 million
Interest expense of approximately $7 million

For earnings history and earnings-related data on Dynavax (DVAX) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Rivian raises 2026 delivery outlook after Q2 results top guidance
• Danone SA (BN:FP) (DANOY) PT Raised to EUR63 at Deutsche Bank